Satoh Mamoru, Takahashi Yuji, Tabuchi Tsuyoshi, Minami Yoshitaka, Tamada Makiko, Takahashi Kan, Itoh Tomonori, Morino Yoshihiro, Nakamura Motoyuki
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan.
†Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.
Clin Sci (Lond). 2015 Jul;129(2):93-105. doi: 10.1042/CS20150027.
Coronary artery disease (CAD) is the leading cause of death worldwide. The efficacy and safety of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) in primary and secondary prevention of CAD are confirmed in several large studies. It is well known that statins have some pleiotropic, anti-atherosclerotic effects. We review the molecular mechanisms underlying the beneficial effects of statins revealed in recently published studies. Endothelial cell injury is regarded as the classic stimulus for the development of atherosclerotic lesions. In addition, the inflammatory process plays an important role in the aetiology of atherosclerosis. In particular, chronic inflammation plays a key role in coronary artery plaque instability and subsequent occlusive thrombosis. Our previous reports and others have demonstrated beneficial effects of statins on endothelial dysfunction and chronic inflammation in CAD. A better understanding of the molecular mechanism underlying the effectiveness of statins against atherosclerosis may provide a novel therapeutic agent for the treatment of coronary atherosclerosis. The present review summarizes the cellular and molecular mechanism of statins against coronary atherosclerosis.
冠状动脉疾病(CAD)是全球范围内主要的死亡原因。他汀类药物(3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂)在CAD一级和二级预防中的疗效及安全性已在多项大型研究中得到证实。众所周知,他汀类药物具有多种抗动脉粥样硬化的作用。我们回顾了近期发表的研究中揭示的他汀类药物有益作用的分子机制。内皮细胞损伤被视为动脉粥样硬化病变发展的经典刺激因素。此外,炎症过程在动脉粥样硬化的病因学中起重要作用。特别是,慢性炎症在冠状动脉斑块不稳定及随后的闭塞性血栓形成中起关键作用。我们之前的报告及其他研究已证明他汀类药物对CAD患者的内皮功能障碍和慢性炎症具有有益作用。更好地理解他汀类药物抗动脉粥样硬化作用的分子机制可能为冠状动脉粥样硬化的治疗提供一种新型治疗药物。本综述总结了他汀类药物抗冠状动脉粥样硬化的细胞和分子机制。